Compare USPH & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | USPH | ABCL |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1992 | 2020 |
| Metric | USPH | ABCL |
|---|---|---|
| Price | $82.44 | $3.91 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 5 |
| Target Price | ★ $106.50 | $7.75 |
| AVG Volume (30 Days) | 213.3K | ★ 5.0M |
| Earning Date | 02-25-2026 | 02-24-2026 |
| Dividend Yield | ★ 2.17% | N/A |
| EPS Growth | ★ 153.49 | N/A |
| EPS | ★ 2.38 | N/A |
| Revenue | ★ $750,948,000.00 | $35,325,000.00 |
| Revenue This Year | $19.53 | $25.45 |
| Revenue Next Year | $6.33 | $10.07 |
| P/E Ratio | $34.94 | ★ N/A |
| Revenue Growth | ★ 17.51 | 7.17 |
| 52 Week Low | $62.77 | $1.89 |
| 52 Week High | $93.50 | $6.52 |
| Indicator | USPH | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 47.39 | 46.75 |
| Support Level | $84.94 | $3.92 |
| Resistance Level | $88.69 | $4.25 |
| Average True Range (ATR) | 3.10 | 0.31 |
| MACD | -0.41 | -0.03 |
| Stochastic Oscillator | 28.54 | 5.50 |
US Physical Therapy Inc through its subsidiaries operates outpatient physical therapy clinics that provide pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries. The principal payment sources for the clinics' services are managed care programs, commercial health insurance, Medicare/Medicaid, workers' compensation insurance, and proceeds from personal injury cases. Its operating segment includes Physical therapy operations and Industrial injury prevention services. The company generates maximum revenue from the Physical therapy operations segment.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.